Iranian National Science Foundation, Tehran, Iran.
Department of Biochemistry and Nutrition, School of Medicine, Zanjan University of Medical Sciences, Zanjan, Iran.
Biol Trace Elem Res. 2018 Feb;181(2):288-295. doi: 10.1007/s12011-017-1059-2. Epub 2017 Jun 2.
Studies have shown that non-alcoholic fatty liver disease (NAFLD) patients are more prone to cardiovascular disease (CVD). Zinc and selenium deficiency are common in NAFLD. But the effects of zinc and selenium co-supplementation before and/or after disease progression on CVD markers are not clear in NAFLD patients. This study aimed to compare the effects of zinc and selenium co-supplementation before and/or after disease progression on some of the CVD markers in an experimental model of NAFLD. Forty male Sprague Dawley rats (197 ± 4 g) were randomly assigned into four dietary groups: control group (C; received 9% of calorie as fat), model group (M; received 82% of calorie as fat), and supplementation before (BS) or after (AS) disease progression. Animals were fed diets for 20 weeks in all groups. Fasting plasma glucose (FPG), insulin, HOMA-IR, ALT, AST, lipid profile, malondialdehyde (MDA) and vascular endothelial growth factor (VEGF) levels were measured as CVD indices. Serum ALT, AST, FPG, insulin, MDA, VEGF and HOMA-IR were significantly higher in the M than C group. Co-supplementation reduced serum ALT and AST levels in the BS and AS groups compared with the M group. FPG, insulin, HOMA-IR, VEGF, MDA, LDL/HDL-c and TC/HDL-c ratio were significantly reduced in the AS compared with the M group. TG/HDL-c ratio was significantly reduced in the BS and AS compared with the M group. Serum MDA, VEGF, Insulin and HOMA-IR were significantly lowered in the AS than BS group (p < 0.05). Zinc and selenium co-supplementation after NAFLD progression reduced CVD risk indices in an experimental model.
研究表明，非酒精性脂肪性肝病（NAFLD）患者更容易患心血管疾病（CVD）。锌和硒缺乏在 NAFLD 中很常见。但是，在 NAFLD 患者中，疾病进展前后补充锌和硒对 CVD 标志物的影响尚不清楚。本研究旨在比较疾病进展前后补充锌和硒对 NAFLD 实验模型中一些 CVD 标志物的影响。将 40 只雄性 Sprague Dawley 大鼠（197±4g）随机分为四组：对照组（C；摄入 9%的卡路里作为脂肪）、模型组（M；摄入 82%的卡路里作为脂肪）、疾病进展前（BS）或疾病进展后（AS）补充组。所有组的动物均喂食 20 周的饮食。空腹血糖（FPG）、胰岛素、HOMA-IR、ALT、AST、血脂谱、丙二醛（MDA）和血管内皮生长因子（VEGF）水平作为 CVD 指标进行测量。与 C 组相比，M 组血清 ALT、AST、FPG、胰岛素、MDA、VEGF 和 HOMA-IR 显著升高。与 M 组相比，BS 和 AS 组的血清 ALT 和 AST 水平降低。与 M 组相比，AS 组的 FPG、胰岛素、HOMA-IR、VEGF、MDA、LDL/HDL-c 和 TC/HDL-c 比值显著降低。与 M 组相比，BS 和 AS 组的 TG/HDL-c 比值显著降低。与 BS 组相比，AS 组的血清 MDA、VEGF、胰岛素和 HOMA-IR 显著降低（p<0.05）。NAFLD 进展后补充锌和硒可降低实验模型中的 CVD 风险指数。
